- A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. Fiedler, W., Tchen, N., Bloch, J., Fargeot, P., Sorio, R., Vermorken, J.B., Collette, L., Lacombe, D., Twelves, C. Eur. J. Cancer (2006)